Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
July 25, 2017 1:51 PM EDTBMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $67.00 (from $62.00) while maintaining a Outperform rating.
Analyst Do Kim recommends buying on weakness following Biogen comments on Spinraza growth to slow in 2H17.
"We believe Spinraza has... More
Ionis (IONS) Partner Biogen Reports Blow-Out Spinraza Sales - BMO Capital
July 25, 2017 7:50 AM EDTBMO Capital analyst Do Kim notes Ionis Pharmaceuticals (NASDAQ: IONS) partner Biogen reported 2Q17 Spinraza sales of $203mn, easily beating our $71mn and Street's $75mn.
"Even with rising expectations heading into BIIB's earnings, Spinraza exceeded growing buyside estimates of $100-150mn.... More
